4,463 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 4,463 shares of the medical research company’s stock, valued at approximately $1,077,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Frank Rimerman Advisors LLC raised its position in shares of Bio-Rad Laboratories by 3.0% during the second quarter. Frank Rimerman Advisors LLC now owns 1,806 shares of the medical research company’s stock valued at $436,000 after buying an additional 53 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Bio-Rad Laboratories by 1.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,871 shares of the medical research company’s stock valued at $693,000 after acquiring an additional 54 shares during the last quarter. M&T Bank Corp lifted its stake in Bio-Rad Laboratories by 3.7% in the 2nd quarter. M&T Bank Corp now owns 1,855 shares of the medical research company’s stock worth $447,000 after purchasing an additional 66 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. Finally, UMB Bank n.a. boosted its holdings in shares of Bio-Rad Laboratories by 89.8% during the 2nd quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 79 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $308.05 on Monday. The business’s 50 day moving average price is $315.47 and its 200-day moving average price is $281.31. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $373.69. The company has a market cap of $8.31 billion, a P/E ratio of -12.67 and a beta of 1.18. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.94 and a current ratio of 5.44.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.The company had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. During the same quarter in the prior year, the business earned $2.01 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BIO shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 8th. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Citigroup increased their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company raised their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Finally, Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, November 22nd. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bio-Rad Laboratories has an average rating of “Hold” and a consensus price target of $358.50.

Insider Activity at Bio-Rad Laboratories

In related news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $306.18, for a total transaction of $214,326.00. Following the completion of the transaction, the executive vice president directly owned 510 shares of the company’s stock, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 17.83% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.